Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2009-11-01

Last Posted Date: 2013-12-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 256

Registration Number: NCT01005680

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sichuan, China

Low Dose Weekly Docetaxel Versus Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer

Not Applicable

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: docetaxel
Drug: pemetrexed

First Posted Date: 2009-10-30

Last Posted Date: 2009-10-30

Lead Sponsor: Chang Gung Memorial Hospital

Target Recruit Count: 179

Registration Number: NCT01004601

Locations: 🇨🇳
Chang Gung Memorial Hospital, Taipei, Taiwan

A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Cisplatin
Drug: Bevacizumab

First Posted Date: 2009-10-29

Last Posted Date: 2014-05-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 109

Registration Number: NCT01004250

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Solna, Sweden

A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Cisplatin
Radiation: Thoracic Radiotherapy

First Posted Date: 2009-10-23

Last Posted Date: 2014-04-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 90

Registration Number: NCT01000480

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain

A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy

Phase 2

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Cisplatin
Drug: Bevacizumab

First Posted Date: 2009-10-20

Last Posted Date: 2024-07-30

Lead Sponsor: Columbia University

Target Recruit Count: 12

Registration Number: NCT00998166

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
North Shore University Hospital, Lake Success, New York, United States

NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: NGR-hTNF
Drug: Cisplatin
Drug: Gemcitabine
Drug: Pemetrexed

First Posted Date: 2009-10-14

Last Posted Date: 2018-09-27

Lead Sponsor: AGC Biologics S.p.A.

Target Recruit Count: 121

Registration Number: NCT00994097

Locations: 🇮🇹
Fondazione San Raffaele del Monte Tabor, Milan, Italy
🇮🇹
Istituto Europeo Oncologico, Milan, Italy
🇮🇹
Istituto Nazionale per la ricerca sul cancro, Genoa, Italy

and more 1 locations

A Study of Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: LY2603618
Drug: Pemetrexed

First Posted Date: 2009-10-02

Last Posted Date: 2019-09-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 55

Registration Number: NCT00988858

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan